Membrane-proximal external region is a superior target for mediating effector activity of HIV-1 specific chimeric antigen receptor modified T cells.

Emiko Kranz^{1,2}, Joshua Chan^{1,2}, Maya Hashimoto^{1,2}, Toshio Kanazawa^{1,2}, Hanlu Wang^{1,2}, and Masakazu Kamata^{1,2,#*}

¹Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

²UCLA AIDS Institute, Los Angeles, CA 90095, USA

#Current Address: Department of Microbiology, University of Alabama at Birmingham, AL 35205, USA

*Corresponding author

E-mail: masa3k@uab.edu

Abstract

The use of chimeric antigen receptor modified-T (CAR-T) cells in adoptive immunotherapy has been popularized through recent success in the field of cancer treatment research. CD4ζ CAR, which targets HIV-1-infected cells, has been developed and evaluated in patients. Though well-tolerated for over a decade, efficacy was disappointingly limited. This result encourages us to develop a novel CAR more effective than CD4ζ CAR. To quantitatively compare anti-HIV-1 activity of different CAR constructs in a highly sensitive and reproducible manner, we developed a multicolor flow cytometry

method for assessing anti-HIV-1 effector T-cell activity. “Target” Jurkat cells inducibly expressing an HIV-1_{HXB2} envelope protein and “Non-target” control cells were genetically labeled with red and blue fluorescent protein, respectively, and co-incubated with human primary T cells transduced with anti-HIV-1 “Effector” CARs at various Effector vs Target cell ratios. Absolute cell numbers of each population were collected by MACSQuant Analyzer and used for calculation of relative cytotoxicity. We successfully ranked the cytotoxicity of three previously reported single chain-antibody CARs and six newly developed single-domain antibody CARs in comparison to CD4ζ CAR. Interestingly, three CARs—10E8, 2E7, and 2H10—which demonstrate high cytotoxic activity were all known to target the membrane-proximal external region. Use of this novel assay will simplify assessment of new CAR constructs and in turn accelerate the development of new effective CARs against HIV-1.

Author Summary

Adoptive immunotherapies that utilize autologous T cells expressing a desired antigen-specific CAR aim to elicit directed immune responses. In recent years, CAR immunotherapies have been promoted extensively in B cell malignancy treatments. The HIV-1-targeting CAR, known as CD4ζ, was developed over 20 years ago and has been widely and longitudinally tested in patients. However, its effectiveness was hindered by poor survival and functionality of the transduced cells. To conduct quantitative evaluation of newly designed anti-HIV-1 CARs, we developed a novel multicolor flow-based assay for HIV-1-specific cytotoxicity, enabling sensitive and quantitative assessment in a high-throughput fashion. This assay would be also useful in screening HIV-1-targeting immune

receptors—including CARs and T cell receptors—and other immunotherapeutic drugs such as anti-HIV-1 antibodies.

Introduction

Chimeric antigen receptors (CARs) are artificially engineered receptors that confer a desired specificity to immune effector T cells such as CD4⁺ (as a helper T cell) and CD8⁺ (as a cytotoxic T cell) [1-6]. When a CAR encounters its target ligand, it signals the cell in a T cell receptor (TCR)-like manner, but not in a human leukocyte antigen (HLA)-dependent manner; thus, this approach can be utilized in treatments for anyone. The use of CAR-modified T (CAR-T) cells has been applied extensively in anti-cancer research, such as with solid organ tumors and lymphomas [6-12].

A promising candidate for use in anti-HIV-1 adoptive therapy is the CD4 ζ CAR, which contains extracellular domains from CD4, a major HIV-1 receptor, and an internal signaling domain derived from CD247, a CD3 ζ -chain. CD4 ζ CAR utilizes the CD4 recognition site to respond to an HIV-1 envelope protein that lies on the exposed surface of infected cells. Once activated, the ζ -chain emits a signal to trigger potent effector function against infected cells [13-21]. This CAR has been widely and longitudinally tested in patients over 500 patient years [22-25]. Treatment was safe and well-tolerated for over a decade, but antiviral effects were limited, most likely due to poor maintenance of gene-modified cells. These results facilitated the restructuring of CD4 ζ CAR to preserve its inherent potential as well as to heighten its antiviral capabilities, leading to the creation of a new CAR line: novel anti-HIV-1 CARs using a single chain (scFv) form of broadly neutralizing antibodies (bNAbs) [26-29].

Cytotoxic assays are used to determine the efficiency of a CAR's cytotoxic activity by observing its ability to kill "Target" cells that express the epitope recognized by a corresponding "Effector" CAR. The radioactive chromium (^{51}Cr)-release method developed in 1968 has traditionally been used to determine the cytotoxic activity of effector cells[30]. Although the assay is reliable and has become a "gold standard," it has a number of disadvantages and functional limitations such as low sensitivity, risk of radioactive contamination, and spontaneous release of ^{51}Cr contributing to heightened background levels that tend to limit its application in quantitative assessment and high-throughput screening. To overcome these issues, several nonradioactive methods have been developed that mainly use fluorescent dyes [31-42]. However, despite the advantage of working with nonradioactive material, these methods have not yet found a broad acceptance—likely due to the labor-intensive procedure, wide variability across assays, and low reproducibility in results.

To perform quantitative evaluation of newly designed CARs with high reproducibility and accuracy, we developed a novel multicolor flow cytometry-based assay for HIV-1-specific effector activity. The assay uses two cell lines: "Target", which is genetically labeled by a red-fluorescent protein (mCherry) and inducibly expresses HIV-1_{HXB2} envelope proteins, and "Non-target," which is labeled by a blue fluorescent protein (TagBFP) but does not express the HIV-1 envelope proteins. To minimize non-specific cell death by mismatched major-histocompatibility complex (MHC), the surface expression of MHC was first eliminated from both Non-target and target cells by knocking out the $\beta 2$ microglobulin ($\beta 2\text{MG}$) gene with CRISPR gene editing technology[43]. In addition, low CD4-expressing populations of these cells were further selected to minimize

spontaneous cell death initiated by HIV-1 envelope mediating cell fusion[44]. Equal numbers of Target and Non-target cells are co-incubated with CAR-T effector cells in various ratios for 16 hours. HIV-1-specific cytotoxicity is determined by counting absolute cell numbers of each population. This assay enables assessment of HIV-1-specific cytotoxicity at a single cell level, allowing for quantitative and simple numerical analysis of results rather than relying on measurements of a released substance. These benefits expand the applicability of the assay, allowing for personalization according to the samples present without sacrificing efficiency.

Results

Generation of target cells for HIV-1-specific effector cell assay.

The ^{51}Cr -release assay has been known as the gold standard for evaluating effector T cell activity [30]. The main difficulty with the ^{51}Cr assay lies in the complications that arise from variation in ^{51}Cr labeling due to spontaneous release of ^{51}Cr , elevating background levels substantially. The success and analytical quality of flow cytometry-based assays hinges considerably on the reproducibility of results—the basis of this consistency lies in the quality of an assay's Target cell population. To remedy these issues presented by the ^{51}Cr assay, we have developed a novel cell line stably expressing fluorescent protein that is not spontaneously released, unless the integrity of the cell surface membrane is compromised due to attacks by such as cytotoxic T cells. We utilized two different Jurkat cell lines previously established: Target, which inducibly expresses HIV-1_{HXB2} envelope proteins upon doxycycline (DOX) removal from the culture medium, and Non-target, which does not express the HIV-1 envelope proteins [45]. To minimize

cytotoxicity mediated by allogeneic reactions because of mismatched MHC, we first eliminated MHC surface expression via gene targeting of β 2MG using CRISPR/Cas9 technology (**S1 Fig**). The cells were then modified by genetic labeling with mCherry for Target cells (HXBC2) or TagBFP for Non-target cell (Δ KS). Fluorescently labeled populations with missing HLA expression were sorted by FACS Aria II along with a CD4 dimmer population to minimize cell fusion induced by the interaction between HIV-1 envelope and CD4 (**Figs 1B,C**). HIV-1 envelope protein expression of resultant cells was confirmed by western blotting using antibodies against HIV-1 gp120 (2G12) and gp41 (2F5) 4 days after removal of doxycycline (DOX) from the culture medium (**Fig 1D**) as well as flow cytometry using a fusion protein of soluble human CD4 and Fc portion of human IgG1 (sCD4 Fc), followed by APC-conjugated anti-human Ig Fc (**Fig 1E**). Importantly, levels of HIV-1 envelope expression in HXBC2 on days 9 and 12 were similar to those of primary human CD4 T cells infected by two different HIV-1 strains.

Fig 1. Generation of Jurkat cells inducibly expressing envelope protein from HIV-1_{HXBC2} (HXBC2).

(A) Schematic of lentiviral vectors for expressing TagBFP and mCherry. These vectors have an FG12-derived backbone possessing a self-inactivating LTR, central polypurine tract (cPPT), ubiquitin C promoter (UbiC), and a mutant Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPPE). **(B)** Jurkat cells with or without inducibly expressing envelope protein from HIV-1_{HXBC2} first had human- β 2 microglobulin (β 2MG) expression knocked out by CRISPR-Cas9 gene editing using a non-integrating lentiviral vector encoding Cas9 together with sgRNA specific for β 2MG as shown in **S1 Fig**.

Populations missing human-leukocyte antigen (HLA)-I A, B, and C expression were negatively enriched by magnetic bead separation, followed by transduction with a lentiviral vector encoding either TagBFP for Δ KS or mCherry for HXBC2. Cells were then labeled by PE/Cy7-conjugated anti-human HLA-I A,B,C and BV711-conjugated human CD4 antibodies then further selected for TagBFP⁺/HLA-I A,B,C/CD4^{dim} (Δ KS) or mCherry⁺/HLA-I A,B,C/CD4^{dim} (HXBC2) populations by FACSAria II flow sorter. **(C)** Equal numbers of Δ KS, HXBC2, and unmodified Jurkat cells were mixed and analyzed on LSRT Fortessa for TagBFP and mCherry expression. **(D)** HXBC2 cells were cultured for 4 days in the presence or absence of 1 μ g/ml doxycycline (DOX) to induce HIV-1_{HXBC2} envelope expression. Five million cells were lysed in 1% CHAPS and HIV-1 envelope expression was analyzed by western blotting using a mixture of anti-HIV-1 gp41 (2F5) and anti-HIV-1 gp120 (2G12) antibodies. Numbers to the right of the picture indicate molecular mass in kilodaltons. +: with DOX, -: without DOX. **(E)** A fusion protein of soluble human CD4 and Fc portion of human IgG1 (sCD4 Fc) was used for detection of HIV-1 envelope expression on cell surface. One million HXBC2 cells cultured in the absence (red) or presence (blue) of DOX for 6, 9, and 12 days were incubated with 1 μ g sCD4 Fc on ice, followed by APC-conjugated anti-human Ig Fc portion. Human primary T cells (two donors) were infected with HIV-1_{AD8} and HIV-1_{BaL} and used as a positive control for levels of cell surface expression of HIV-1 envelope proteins detected by sCD4 Fc. Gray: uninfected human primary T cells, Red: HIV-1-infected cells.

Establishing HIV-1-specific cytotoxicity assay using multicolor flow cytometry.

Assessment of cytotoxicity in our assay is carried out by counting absolute live cell populations in each well following co-culture of “Effector”, “Target”, and “Non-target” cells (**Fig 2**). Target and non-target cells that have been genetically modified to express different fluorescent proteins are easily characterized by multicolor flow cytometry. Upon attack by effector cells, their cytoplasmic contents are released into the supernatant and the number of fluorescent cells decreases, i.e., the loss of fluorescence from cells is used as an indicator of both decreased membrane integrity and cell death [46]. The same numbers (10,000 cells/well in a 96 well plate) of HIV-1 envelope-expressing target cells are co-cultured with non-target cells lacking envelope expression and effector cells designed to eliminate target cells (**Fig 2A**). Isolated populations of target cells are counted against those of non-target cells to evaluate apparent cytotoxic activity following co-culturing with effector cells (**Figs 2B,C**). Our assay is unique not only in its use of uniform fluorescent marking, but also in its utilization of the MACSQuant system for counting actual live cell populations. The greatest advantage of this instrument is the fully automated system, which allows the collection of data in a high throughput manner with easy operation. Use of automated counting by MACSQuant also proves advantageous in its consistency, removing complications by human error.

Fig 2. Schematic outline of a multicolor flow cytometry-based cytotoxicity assay designed for HIV-1 specific CAR-T cells.

(A) Scheme of fluorescent-based cytotoxicity assay. TagBFP⁺ control Jurkat cells (Δ KS; Non Target) and mCherry⁺ Jurkat cells that inducibly express HIV-1_{HXBC2} envelope protein upon removal of DOX from culture medium (HXBC2; Target). Δ KS and HXBC2 cells were

co-incubated together with human primary T cells transduced with a vector encoding CD4ζ CAR or a control EGFP vector (CD4ζ or EGFP). (**B,C**) Absolute cell number of each population circled in blue (Non-target) or red (Target) was analyzed by MACSQuant. HIV-specific cytotoxicity was calculated as relative cytotoxicity as follows: Relative cytotoxicity (%) = 100 x (1 - Target cell numbers/Non-Target cell numbers). The uncircled population is composed of effector cells. Data represent the mean ± standard deviation from triplicate wells.

The assay shows high reproducibility with wide dynamic range.

A comparative assay system relies heavily on consistency of results; such consistency may be assured by adjusting variables that the cytotoxic effect depends on. Before we use the above established cell lines for further assays, cells were processed to isolate single-clone populations since bulk populations consist of heterogeneous cells that affect the cytotoxicity assay (**Fig 3**). Based on levels of HIV-1 envelope expression and sensitivity to CD4ζ CAR-mediated cytotoxicity, we selected HXBC2 clone #39 and ΔKS clone #13 for later experiments. Clone #39 showed stable HIV-1 envelope expression over 7 days after 8 to 10 days of culture with medium containing no DOX (**Fig 3B**) and was able to mediate HIV-1-specific T cell proliferation (**Fig 3C**). HIV-1 specific cytotoxicity was confirmed after 8 hours of incubation with CD4ζ CAR-expressing T cells and plateaued after 16 hours of incubation (**Fig 3D**).

The critical factor to take into consideration for a reproducible assay is the Effector to Target (E:T) ratio. If there are too few effector cells, cytotoxic activity will appear inefficient and produce inconclusive results; however, if there are too many effector cells,

non-target cells are at risk of collateral cytotoxic effect, resulting in high background signals. This saturation of effector cells may also result in higher levels of cytotoxic effect that do not reveal any further understanding of the tested CAR's efficacy. Should such excessive amounts of effector be used, one would see high levels of killing no matter the actual capabilities of the CAR. Thus, choosing a ratio before effector function plateaus is ideal. Ratios ranged from 2^{-7} to 2^{-2} (0.0078125 to 0.25) and levels of cytotoxicity by CD4 ζ increased in a linear fashion following increased E:T ratio (**Fig 3E**). Although these levels also elevated in controls (**Fig 3E, EGFP**), the differences of relative cytotoxicity between CD4 ζ and EGFP control increased in a linear fashion from 2^{-7} to 2^{-3} and reached a plateau (**Fig 3E, Difference**). We therefore used the E:T ratios from 2^{-7} to 2^{-3} thereafter.

Fig 3. Characterization of single cell-derived HXBC2 cells.

Single cell-derived clone for Target (HXBC2 #39) and Non-Target (Δ KS #13) cells was obtained by limiting dilution. **(A)** HXBC2 #39 cells were cultured in medium with no DOX for 10 days. HIV-1 envelope expression was monitored by sCD4 Fc/APC staining as described in **Figure 1** (red). Uninduced HXBC2 #39 cells were used as a negative control (gray). **(B)** Surface expression of HIV-1_{HXBC2} envelope protein was monitored daily over 18 days and mean fluorescent intensities (MFIs) were plotted. **(C)** CD4 ζ CAR-expressing human primary T cells were co-cultured with Δ KS #13 or HXBC2 #39 (E:T ratio = 1:10) after labeling with cell proliferation dye eFluor 670. Proliferation of CD4 ζ CAR-T cells was monitored by dye dilution after 6 days culture. **(D,E)** HIV-1-specific cytotoxicity mediated by CD4 ζ CAR was tested with increasing incubation time (8 - 24 hours) **(D)** or different effector:target ratio (E:T ratios = 2^{-7} to 2^{-2}) **(E)**. Results were calculated as a relative

cytotoxicity as described in **Fig 2** and shown by the mean $\pm$ standard deviation from triplicate wells.

Anti-HIV-1 CARs targeting gp41 MPER exert a potent anti-HIV-1 specific cytotoxicity.

Anti-HIV-1 antibodies neutralizing wide-spectrum of HIV-1 strains called broadly-neutralizing antibodies (bNAbs) have been developed or isolated from HIV-1-infected individuals. These antibodies are known to recognize diverse epitopes on HIV-1 envelope proteins to differing extents and are utilized for developing a variety of anti-HIV-1 CARs [47]. Prior to developing novel anti-HIV-1 CARs using bNAbs, we first tested whether previously reported anti-HIV-1 bNAbs can recognize HIV-1 envelope proteins expressed on cells (**Fig 4**).

We selected 10 different bNAbs based on their efficacies as well as a broad spectrum, including two different forms of antibody, conventional antibody and heavy-chain antibody [48, 49]. For CAR designing, the single-chain variable fragment (scFv) form or single-domain antibody (sdAb) form of these antibodies have been used.. Therefore we developed the scFV or sdAb forms of these antibodies and assessed whether they can recognize HIV-1 envelope proteins expressed on cell surface by flow cytometry. A portion of epitope receptor of scFv or sdAb form was conjugated to a common human immunoglobulin G1 (IgG1) Fc domain—termed synthetic-antibody mimetics (SyAMs)—allowing for quantitative immunological assays. All SyAMs can be enriched at >95% purity, as determined by SDS-PAGE gel, using a protein-A column (**Figs 4B,C**). HXBC2 #39 clone induced with envelope expression for 10 days were used

for assessing the levels of epitope detection by those anti-HIV-1 SyAMs. Although epitope recognition differed between SyAMs, most were able to detect HXBC2 cells expressing HIV-1_{HXBC2} envelope proteins.

Three scFv and six sdAb fragments were then subcloned into the CD4 ζ vector by replacement of the EGFP-P2A-CD4 fragment (**Fig 5A**). To improve CAR-T cell survival and their effector activities, all these CARs, including CD4 ζ , included the 41BB costimulatory signaling domain inserted between the CD8 transmembrane domain and ζ -chain [50, 51]. To protect CAR-T cells from HIV-1 infection as well as virus production from proviral genes, all vectors included two anti-HIV-1 genes, C46 fusion inhibitor [52, 53] and shRNA against the LTR R region (sh516) as reported previously [54, 55]. The C46 gene was selected as the best inhibitor for HIV-1 infection in comparison with three other inhibitors: shRNA against CCR5 (sh1005) [56, 57], V2o[58], and AP3[59] (**S2 Fig**). All of these CARs were successfully expressed in human primary T cells at similar levels (**Fig 5B**).

Anti-HIV-1-specific effector activity of each CAR was ranked by a cytotoxicity assay developed above using CD4 41BB ζ CAR as a reference CAR. To input the same number of effector cells in the assay, percent positivity of effector cells in each well was adjusted by unmodified mock T cells. 10E8 41BB ζ CAR showed near 2-fold higher activity than that of CD4 41BB ζ CAR. PGT128 and 3BNC117 41BB ζ CARs showed a weak to no detectable cytotoxicity. 10E8 and PGT128 41BB ζ CARs were further evaluated for cytokine production (**Fig 5D**). Compared to the no-CAR control (**Fig 5A, EGFP**), CD4⁺ and CD8⁺ T cells modified with these CARs successfully produced cytokines in response to induced HXBC2 cells expressing HIV-1 envelope proteins. Interestingly, there was no

clear correlation between levels of cytokine production and induction of cytotoxicity; PGT128 CAR showed weaker effector activity than 10E8 CAR, but similar levels of IFN- γ and TNF- α , both are well-known pro-inflammatory cytokines [60], production in both CD4 and CD8 T cells.

Lastly we tested sdAb-based CARs in the same way. Overall, slightly lower levels of gene marking were seen with these CARs (**Fig 6B**), probably due to the use of different assay methods between scFv and sdAb CARs (see **Materials and Methods**). As seen with 10E8 41BB ζ CAR, both MPER-specific sdAb-based CARs, 2H10 and 2E7, showed around 2-fold higher activity in comparison to that of CD4 41BB ζ CAR. Except J3 41BB ζ CAR, the three other CARs (1F10, JM4, and 1H9) exhibited similar levels of effector activity in comparison to that of CD4 41BB ζ CAR (**Figs 6C,D**).

Fig 4. Binding features of anti-HIV-1 broadly neutralizing antibodies (bNAbs) to HIV-1_{HXBC2} envelope proteins expressed on HXBC2 #39 clone cells.

(A) A list of anti-HIV-1 bNAbs used in this experiment. Recombinant forms of anti-HIV-1 bNAbs were expressed in 293T cells as a fusion protein with the Fc portion of human IgG1 and purified by protein A column. scFv: single-chain variable fragment. sdAb: single-domain antibody. **(B,C)** HXBC2 #39 cells were cultured in the absence of DOX for 10 days to induce HIV-1_{HXBC2} envelope protein. One million cells were incubated with 1 μ g of each antibody on ice for 1 hour followed by APC-conjugated anti-human IgG Fc portion (red). Soluble CD4 Fc (sCD4) was used as a positive control and human IgG was used as a negative control. Uninduced HXBC2 #39 cells cultured in the presence of DOX were used to monitor non-specific antibody binding (blue).

299

300 **Fig 5. HIV-1-specific cytotoxicity mediated by anti-HIV-1 scFv CAR-T cells.**

301 **(A)** Schematic of anti-HIV-1 CAR structures expressed in lentiviral vectors. EGFP and
 302 CD4 ζ serve as negative and positive controls. CD4 41BB ζ CAR contains 4-1BB domain
 303 derived from human CD137. Three other CARs—10E8 41BB ζ , PGT128 41BB ζ , and
 304 3BNC117 41BB ζ —encode single-chain forms of anti-HIV-1 bNAbs. **(B)** Transduction
 305 levels of each anti-HIV-1 CAR were monitored by flow cytometry. EGFP, CD4 ζ , or CD4
 306 41BB ζ transduction were monitored by EGFP expression. Three anti-HIV-1 scFv CARs
 307 were detected by staining with Alexa488-conjugated anti-human Fc portion. **(C)**
 308 Comparison of the specific cytotoxicity induced by anti-HIV-1 CAR. Data represent the
 309 mean $\pm$ standard deviation from triplicate wells. **(D)** Production of three different cytokines
 310 (IFN- γ , IL-2, and TNF- α) in CAR-modified CD4 and CD8 T cells was monitored by flow
 311 cytometry. Data were shown by % positivity of cytokine-producing cells.

312

313 **Fig 6. Superior anti-HIV-1 activity mediated by MPER-targeting anti-HIV-1 CAR.**

314 **(A)** A list of anti-HIV-1 sdAbs used for anti-HIV-1 CAR design. **(B)** Transduction levels of
 315 each anti-HIV-1 sdAb CAR were monitored by flow cytometry. Surface expression of anti-
 316 HIV-1 sdAb CARs was detected by biotinylated-protein L, followed by APC-conjugated
 317 streptavidin. **(C)** Comparison of specific cytotoxicity induced by anti-HIV-1 sdAb CARs.
 318 **(D)** Comparison of specific cytotoxicity induced by MPER-targeting anti-HIV-1 CARs.
 319 Data represent the mean $\pm$ standard deviation from triplicate wells.

320

321 **Discussion**

In recent years, CAR technology has been extensively expanded as an HIV-1 curative therapy [13, 15, 16, 26, 27, 47, 61-63]. Various anti-HIV-1 CARs targeting multiple different epitopes have been designed and evaluated their effector activities in vitro and in vivo systems (See review[47]). However the different assay systems easily generate conflicting conclusions even using the same source of antibody for CAR design [20, 27, 47, 64, 65]. To obtain highly reproducible result, we first selected single cell clones which can stably express HIV-1 envelope proteins over 7 days upon DOX removal from the culture medium, named HXBC2 #39. We eliminated HLA surface expression and minimized levels of CD4 surface expression, resulting in low levels of CAR-independent cytotoxicity mediated by mismatched HLA or CD4-dependent syncytium formation. As a result, this cell enabled assessment of HIV-1 specific effector activity even at low E:T ratios (**Fig 3E**). The combination with accurately countable multicolor flow cytometry allowed us to provide quantitative and reproducible results with wide-dynamic range and low background. Importantly, any residual background mediated by CAR-independent cytotoxicities can easily be compensated by using an appropriate range of E:T ratios. With this assay, we successfully ranked 9 newly designed anti-HIV-1 CARs targeting various regions of HIV-1 envelope proteins. Three CARs targeting the MPER of gp41 showed approximately 2-fold higher activity than CARs targeting other regions of HIV-1 envelope proteins (**Figs 5 and 6**). Importantly, these results were obtained from two different CAR backbones constructed by scFv (10E8) or sdAb (2E7 & 2H10), suggesting that the MPER can be a good target for designing anti-HIV-1 CAR or other anti-HIV-1 biologics such as HIV-1 specific antibodies with effector activities.

In general, bNAbs targeting MPER are known to be more effective against broader range of HIV-1 strains but less effective and also display autoreactivity or polyreactivity [66, 67]. A similar observation was confirmed when the scFv form of 10E8 was tested for staining of HIV-1_{HXBC2} envelope proteins expressed on HCBX2#39 cells (**Fig 4B**). Whereas we did not observe such negative features with our three MPER CARs; they showed more potent anti-HIV-1 effector activity than other CARs. Such difference may be caused by the different mechanisms of action between neutralization and effector activity mediated by CAR format.

Our assay is suitable to evaluate anti-HIV-1 effector activity against HIV-1_{HXBC2} infection, and further validation is required against other virus strains. The bNAbs used here for designing anti-HIV-1 CARs are known to be effective against broad spectrum of HIV-1, and we expect that these CARs selected via our assay would be effective against other strains. Whereas one type of CAR would not be able to cover all HIV-1 species, the combination of two or three different anti-HIV-1 CAR molecules may be necessary to cover HIV-1 quasispecies within patients as used with the treatment by bNAbs. Since hundreds of anti-HIV-1 bNAbs are now been available for designing new CARs [68], our novel assay should be very powerful for selection of functional CAR molecules which cannot be identified by binding feature to epitope or neutralization activity. For further efficient CAR screening, it would be important to design additional target cells expressing more variety of HIV-1 envelope proteins, for example a CCR5 tropic HIV-1 strain. By marking other target cells with different fluorescent protein, we can assess multiple anti-HIV-1 CARs at the same time in the same assay system. CRISPR/Cas9 technology would be useful to modify the envelope sequence in HXBC2 #39 cells. It is also possible to

generate patient specific target cells with the same system. As such, our assay is able to proceed developing further effective anti-HIV-1 CARs even in a tailor made fashion.

Materials and Methods

Cell preparation and culture. Jurkat cells inducibly expressing envelope of HIV-1_{HXBC2} (NIH AIDS Reagent: #3953) by the removal of doxycycline (DOX) from culture medium were used as a parental cell for an HIV-1 specific target cell (designated as HXBC2). Jurkat cells missing the envelope expression were used as a parental cell for non-target control (AIDS Reagent: #3954, designated as ΔKS). The HLA-Class I expression of these cells were first eliminated by gene targeting of human-β2 microglobulin using CRISPR/Cas9 technology [69]. These cells were then genetically marked by fluorescent proteins, mCherry and TagBFP, respectively, to allow counting of absolute cell numbers of each populations by flow cytometry. HXBC2 cells were gene marked by two red fluorescent proteins for superior detection on MACSQuant analyzer 10 or MACSQuant VYB (MiltenyiBiotec). The cells were stained by anti-HLA-A,B,C antibody (W6/32, Biolegend) and anti-human CD4 antibody (RPA-T4, Biolegend), and populations with the double negative for HLA-A,B,C and CD4, but with the positive for mCherry or TagBFP were sorted out by the BD FACSAria II (BD Biosciences). Bulk sorted populations were further separated into single clone populations by a limiting dilution. Each clone was tested in an assay for induction of HIV-1_{HXBC2} envelope expression as well as CD4ζ CAR-induced cytotoxicity to confirm specificity and sensitivity for CAR-T inducing cytotoxicity. Absolute counts of the target and non-target cell populations were taken by MACSQuant and used to calculate relative cytotoxicity.

HXBC2 and ΔKS cells were maintained in Iscove's Modified Dulbecco's Medium (IMDM) (Invitrogen) supplemented with 15% fetal bovine serum (FBS) (Omega Scientific), Antibiotic-Antimycotic (ThermoFisher Scientific), Glutamax (ThermoFisher Scientific), 100 μg/ml of Hygromycin B (ThermoFisher Scientific), 100 μg/ml of Geneticin® (ThermoFisher Scientific), and 1 μg/ml of DOX (D3072, Sigma-Aldrich). All cells were incubated at 37°C and 5% CO₂.

A lentiviral vector encoding anti-HIV-1 CAR was transduced and expressed in the enriched total human T cells obtained from fresh peripheral blood mononuclear cells by negative selection (EasySep Human T cell isolation kit, Stemcell Technologies). CAR-T cells were maintained in IMDM supplemented with 20% FBS, 30 IU/ml IL-2 (R&D Systems), Glutamax, and Antibiotic-Antimycotic.

Plasmid construction. All vector plasmids were constructed by modifying the FG12 vector [55, 70, 71]. For cell labeling with a fluorescent protein, the cDNAs encoding mCherry [72] or TagBFP [73] were chemically synthesized and cloned into the FG12-based vector under EF-1 α promoter, respectively (GenScript). Fusion inhibitors, C46 [52, 53], V2o[58], and AP3[59] were also chemically synthesized based on the published sequences and cloned into the FG12 vector. A CRISPR/Cas9 lentiviral vector against human-β2 microglobulin was constructed by cloning an expression cassette for both Cas9 and guide RNA (gRNA) of PX458 (Addgene #48138) into the FG12 vector. The target sequence of gRNA was 5'-GAGTAGCGCGAGCACAGCTA-3'. ScFv CARs joined with a 41BB and CD3ζ chain at the C-terminus using human IgG4 Fc portion as a spacer, were inserted into the FG12 vector by swapping with the sequence for CD4ζ-P2A-EGFP [55,

74]. All CAR vectors contain two anti-HIV-1 genes, shRNA against HIV-1-LTR R region to protect CAR-T cells from HIV-1 infection [54, 55, 74] and C46 fusion inhibitor.

Viruses. All lentivirus vectors were produced in 293T cells using calcium phosphate-mediated transient transfection with a packing plasmid (pMDGL), the pRSV-Rev, and the pCMV-VSV-G envelope protein plasmid as previously described [55, 70, 71]. The integration-defective CRISPR/Cas9 vectors were produced using D64E packing plasmid [75]. HIV-1_{AD8} and HIV-1_{BaL} stocks were prepared and infected to human primary CD4+ T cells as previously described [76].

Flow-based cytotoxicity assay. Assay details were summarized in **Fig 2A**. Briefly, each HXBC2 and ΔKS cell was seeded in the same well of round bottom 96-well-plates (#3879, Corning Costar) at a density of 10,000 cells/well in 100 μl of IMDM containing 20% FBS. Effector-T cells modified by anti-HIV-1 CAR or a control vector with different Effector-to-Target ratios (E:T) in the same volume of medium were added to the well and incubated at 37°C (total 200 μl/well). Fifty μl of culture was taken following incubation and fixed in the same volume of 2% formaldehyde/PBS. Absolute cell numbers from each population were analyzed on a MACSQuant Analyzer 10 (Miltenyi Biotec Inc.) using FlowJo (AshLand). Relative cytotoxicity was calculated as a percentage defined by the equation: Relative cytotoxicity = 100 x (1 – target cell number / non target cell number).

SyAM production. All the SyAM constructs were chemically synthesized based upon the public database information available from Los Alamos National Laboratory (<https://www.hiv.lanl.gov/components/sequence/HIV/neutralization/index.html>) and cloned into the FG12 lentiviral vector. SyAM expressing lentiviral vector was transduced to 293T cells at MOI 5. Cells were then cultured in IMDM supplemented with 7% ultra-low IgG FBS

(FB-06, Omega Scientific), Antibiotic-Antimycotic, and Glutamax for 4 days. Recombinant forms of SyAM in culture supernatant were isolated by protein A affinity resins (MabCapture, ThermoFisher Scientific) using Pierce gentle Ag/Ab elution buffer (ThermoFisher Scientific). After dialysis to PBS, SyAMs were concentrated approximately 1 mg/ml with Amicon Ultra Centrifugal Filters (MWCO 30kDa, ThermoFisher Scientific) and stored in -80 °C freezer. Integrity and purify of SyAMs were assessed by SDS-PAGE analysis using 8-16 % gradient gel (Lonza).

Western blot. ΔKS and HXBC2 cells were cultured without DOX for 4 days to induce HIV-1 envelope protein expression. The same number of cells (2×10^6 cells) were lysed in 100 μl of 1% CHAPS/PBS and analyzed on 4-20% SDS-PAGE gel (Lonza). The envelope proteins were detected by 2F5 (specific for gp41, NIH reagent #1475), 2G12 (specific for gp120, NIH reagent #1476), and horseradish peroxidase–conjugated antibody specific for human IgG (Santa Cruz Biotechnology, Dallas) as described previously [77].

Immunofluorescent staining. Cell surface expression of HIV-1_{HXBC2} envelope proteins were detected as follows. One million HXBC2 #39 cells cultured in the absence of DOX for 10 days were incubated with recombinant sCD4 or SyAMs (1 μg each) on ice for 30 min, followed by Alexa488- or APC-conjugated anti-human Fc antibody (Jackson ImmunoResearch Laboratories Inc.). The expression of each anti-HIV-1 CAR was detected by protein L-biotin (GenScript) and Alexa488-conjugated anti-human Fc antibody or APC-conjugated anti-human Fc antibody as described elsewhere [78]. Antibodies for staining of intracellular cytokines, IFN-γ, TNF-α, and IL2, as well as human CD8 were purchased from Biolegend.

HIV-1 specific T-cell proliferation assay. CAR-T cell proliferation assay was performed as follows. HXBC2 #39 or ΔKS #13 cells were cultured in the presence or absence of DOX for 10 days and co-cultured with CD4ζ CAR-T cells pre-labeled with cell proliferation dye eFluor 670 according to the manufacture's instruction (ThermoFisher Scientific) in a 24-well plate over 6 days at E:T ratio = 1:10. Levels of T-cell proliferation in eFluor 670 positive population were monitored by a dye dilution assay using BD Fortessa and analyzed by FlowJo.

Statistical analyses. Results are expressed as mean ± standard deviations (SDs). Errors depict SD. Statistical significance is presented with a *p*-value calculated via GraphPad Prism. The significance of survival-curve data was compared with a log-rank test. All other significance comparisons between groups were calculated by one-tailed unpaired *t*-test with Welch's correction.

Acknowledgments

We thank Jeffrey Brand for editing the manuscript.

References

1. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. *J Immunother.* 2009;32(7):689-702.
2. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a

recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer research. 2011;71(9):3175-81.

3. Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. The New England journal of medicine. 2011;365(20):1937-8; author reply 8.

4. Garfall AL, Stadtmauer EA, June CH. Chimeric Antigen Receptor T Cells in Myeloma. The New England journal of medicine. 2016;374(2):194.

5. Khan M, Mansoor AE, Olson AL. Prospects of chimeric antigen receptor T-cell and natural killer cell therapies in acute leukemias. Future Oncol. 2016;12(19):2179-82.

6. Ruella M, June CH. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. Curr Hematol Malig Rep. 2016;11(5):368-84.

7. Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, et al. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother. 2016;39(5):205-17.

8. O'Hara M, Stashwick C, Haas AR, Tanyi JL. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy. 2016;8(4):449-60.

9. Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(11):2684-96.

10. Ruella M, Levine BL. Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. *Ann Transl Med.* 2016;4(1):13.
11. Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, et al. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. *Cancer immunology research.* 2016;4(8):658-68.
12. Turtle CJ, Riddell SR, Maloney DG. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies. *Clin Pharmacol Ther.* 2016;100(3):252-8.
13. Zhen A, Peterson CW, Carrillo MA, Reddy SS, Youn CS, Lam BB, et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. *PLoS Pathog.* 2017;13(12):e1006753.
14. Zhen A, Rezek V, Youn C, Rick J, Lam B, Chang N, et al. Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model. *J Vis Exp.* 2016(113).
15. Kamata M, Kim PY, Ng HL, Ringpis GE, Kranz E, Chan J, et al. Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4zeta CAR from HIV-1 infection and alleviates impairment of cell proliferation. *Biochemical and biophysical research communications.* 2015;463(3):216-21.
16. Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, et al. HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.

- Molecular therapy : the journal of the American Society of Gene Therapy.
2015;23(8):1358-67.
17. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. *Gene Ther.* 2005;12(4):299-310.
 18. Severino ME, Sarkis PT, Walker BD, Yang OO. Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. *Virology.* 2003;306(2):371-5.
 19. Lin WY, Roberts MR. Developmental dissociation of T cells from B, NK, and myeloid cells revealed by MHC class II-specific chimeric immune receptors bearing TCR-zeta or FcR-gamma chain signaling domains. *Blood.* 2002;100(8):3045-8.
 20. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. *Proc Natl Acad Sci U S A.* 1997;94(21):11478-83.
 21. Tran AC, Zhang D, Byrn R, Roberts MR. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. *Journal of immunology.* 1995;155(2):1000-9.
 22. Mitsuyasu R, Anton P, Deeks S, Scadden D, Connick E, Downs M, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. *Blood.* 2000;96(3):785-93.

23. Walker R, Bechtel C, Natarajan V, Baseler M, Hege K, Metcalf J, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. *Blood*. 2000;96(2):467-74.
24. Deeks S, Wagner B, Anton P, Mitsuyasu R, Scadden D, Huang C, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. *Molecular Therapy*. 2002;5(6):788-97.
25. Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Science translational medicine*. 2012;4(132):132ra53.
26. Liu B, Zou F, Lu L, Chen C, He D, Zhang X, et al. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. *Journal of virology*. 2016;90(21):9712-24.
27. Ali A, Kitchen SG, Chen ISY, Ng HL, Zack JA, Yang OO. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. *Journal of virology*. 2016;90(15):6999-7006.
28. Kumar R, Kumari R, Khan L, Sankhyan A, Parray HA, Tiwari A, et al. Isolation and Characterization of Cross-Neutralizing Human Anti-V3 Single-Chain Variable Fragments (scFvs) Against HIV-1 from an Antigen Preselected Phage Library. *Appl Biochem Biotechnol*. 2019;187(3):1011-27.

29. Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. *Science translational medicine*. 2019;11(504).
30. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. *Immunology*. 1968;14(2):181-96.
31. Burkett MW, Shafer-Weaver KA, Strobl S, Baseler M, Malyguine A. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. *J Immunother*. 2005;28(4):396-402.
32. Godoy-Ramirez K, Makitalo B, Thorstensson R, Sandstrom E, Biberfeld G, Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. *Cytometry A*. 2005;68(2):71-80.
33. Kasatori N, Ishikawa F, Ueyama M, Urayama T. A differential assay of NK-cell-mediated cytotoxicity in K562 cells revealing three sequential membrane impairment steps using three-color flow-cytometry. *J Immunol Methods*. 2005;307(1-2):41-53.
34. Zimmermann SY, Esser R, Rohrbach E, Klingebiel T, Koehl U. A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells. *J Immunol Methods*. 2005;296(1-2):63-76.

35. Zomerdijk JC, Kieft R, Shiels PG, Borst P. Alpha-amanitin-resistant transcription units in trypanosomes: a comparison of promoter sequences for a VSG gene expression site and for the ribosomal RNA genes. *Nucleic acids research*. 1991;19(19):5153-8.
36. Zaritskaya L, Shafer-Weaver KA, Gregory MK, Strobl SL, Baseler M, Malyguine A. Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials. *J Immunother*. 2009;32(2):186-94.
37. Devlin LA, Haughton DJ, Crockard AD, Edgar JD. Natural killer cell cytotoxicity in patients with recurrent herpes infections: diagnostic utility of a flow cytometric assay. *J Clin Pathol*. 2010;63(3):244-8.
38. Ozdemir O. Flow cytometric mast cell-mediated cytotoxicity assay: a three-color flow cytometric approach using monoclonal antibody staining with annexin V/propidium iodide co-labeling to assess human mast cell-mediated cytotoxicity by fluorosphere-adjusted counts. *J Immunol Methods*. 2011;365(1-2):166-73.
39. Jang YY, Cho D, Kim SK, Shin DJ, Park MH, Lee JJ, et al. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells. *Ann Clin Lab Sci*. 2012;42(1):42-9.
40. Thakur A, Zaman A, Hummel J, Jones K, Hortelano G. Single-colour flow cytometric assay to determine NK cell-mediated cytotoxicity and viability against non-adherent human tumor cells. *Biotechnol Lett*. 2012;34(3):447-53.
41. Mhatre S, Madkaikar M, Ghosh K, Desai M, Pujari V, Gupta M. Rapid flow cytometry based cytotoxicity assay for evaluation of NK cell function. *Indian J Exp Biol*. 2014;52(10):983-8.

42. Gillissen MA, Yasuda E, de Jong G, Levie SE, Go D, Spits H, et al. The modified FACS calcein AM retention assay: A high throughput flow cytometer based method to measure cytotoxicity. *J Immunol Methods*. 2016;434:16-23.
43. Wang D, Quan Y, Yan Q, Morales JE, Wetsel RA. Targeted Disruption of the beta2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells. *Stem cells translational medicine*. 2015;4(10):1234-45.
44. Lifson JD, Feinberg MB, Reyes GR, Rabin L, Banapour B, Chakrabarti S, et al. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. *Nature*. 1986;323(6090):725-8.
45. Cao J, Park IW, Cooper A, Sodroski J. Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. *Journal of virology*. 1996;70(3):1340-54.
46. Swearingen KE, Loomis WP, Kehimkar B, Cookson BT, Dovichi NJ. Quantification of green fluorescent protein in cellular supernatant by capillary electrophoresis with laser-induced fluorescence detection for measurement of cell death. *Talanta*. 2010;81(3):948-53.
47. Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, Sommer K, et al. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2017;25(3):570-9.
48. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, et al. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. *PLoS One*. 2012;7(3):e33298.

49. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik D, et al. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. *PloS One*. 2012;7(3):e33298.
50. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). *Cancer research*. 2011;71(13):4617-27.
51. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2009;17(8):1453-64.
52. Wolstein O, Boyd M, Millington M, Impey H, Boyer J, Howe A, et al. Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. *Molecular Therapy-Methods & Clinical Development*. 2014;1:11.
53. Hermann F, Egerer L, Brauer F, Gerum C, Schwalbe H, Dietrich U, et al. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. *Journal of Virology*. 2009;83(10):4844-53.
54. Ringpis G, Shimizu S, Arokium H, Camba-Colón J, Carroll M, Cortado R, et al. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. *PLoS One*. 2012;7(12):e53492.

55. Kamata M, Kim P, Ng H, Ringpis G, Kranz E, Chan J, et al. Ectopic expression of anti-HIV-1 shRNAs protects CD8⁺ T cells modified with CD4 ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation. *Biochemical and biophysical research communications*. 2015;463(3):216-21.
56. An D, Donahue R, Kamata M, Poon B, Metzger M, Mao S, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. *Proc Natl Acad Sci U S A*. 2007;104(32):13110-5.
57. Shimizu S, Kamata M, Kittipongdaja P, Chen K, Kim S, Pang S, et al. Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. *Genetic Vaccines and Therapy*. 2009;7:8.
58. Brauer F, Schmidt K, Zahn RC, Richter C, Radeke HH, Schmitz JE, et al. A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. *Antimicrob Agents Chemother*. 2013;57(2):679-88.
59. Zhu X, Zhu Y, Ye S, Wang Q, Xu W, Su S, et al. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. *Sci Rep*. 2015;5:13028.
60. Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. *Journal for immunotherapy of cancer*. 2018;6(1):56.
61. Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto AJ, et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. *PLoS Pathog*. 2017;13(10):e1006613.

62. Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, et al. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. *Protein & cell*. 2017;8(12):861-77.
63. Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, et al. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. *Journal of virology*. 2015;89(13):6685-94.
64. Roberts M, Qin L, Zhang D, Smith D, Tran A, Dull T, et al. Targeting of human immunodeficiency virus-infected cells by CD8⁺ T lymphocytes armed with universal T-cell receptors. *Blood*. 1994;84(9):2878-89.
65. Hege KM, Cooke KS, Finer MH, Zsebo KM, Roberts MR. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. *The Journal of experimental medicine*. 1996;184(6):2261-9.
66. Zhang R, Verkoczy L, Wiehe K, Munir Alam S, Nicely NI, Santra S, et al. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. *Science translational medicine*. 2016;8(336):336ra62.
67. Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. *Nature immunology*. 2018;19(11):1179-88.
68. Yoon H, Macke J, West AP, Jr., Foley B, Bjorkman PJ, Korber B, et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. *Nucleic acids research*. 2015;43(W1):W213-9.

69. Yan M, Wen J, Liang M, Lu Y, Kamata M, Chen IS. Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs. *PLoS One*. 2015;10(6):e0127986.
70. Kamata M, Liu S, Liang M, Nagaoka Y, Chen I. Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter. *Human gene therapy*. 2010;21(11):1555-67.
71. Kamata M, Liang M, Liu S, Nagaoka Y, Chen I. Live cell monitoring of hiPSC generation and differentiation using differential expression of endogenous microRNAs. *PLoS One*. 2010;5(7):e11834.
72. Shu X, Shaner NC, Yarbrough CA, Tsien RY, Remington SJ. Novel chromophores and buried charges control color in mFruits. *Biochemistry*. 2006;45(32):9639-47.
73. Chai Y, Li W, Feng G, Yang Y, Wang X, Ou G. Live imaging of cellular dynamics during *Caenorhabditis elegans* postembryonic development. *Nat Protoc*. 2012;7(12):2090-102.
74. Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. *Molecular Therapy*. 2015;23(8):1358-67.
75. Poon B, Chen IS. Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. *J Virol*. 2003;77(7):3962-72.
76. Ringpis GE, Shimizu S, Arokium H, Camba-Colon J, Carroll MV, Cortado R, et al. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing

hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One. 2012;7(12):e53492.

77. Kamata M, Watanabe N, Nagaoka Y, Chen I. Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2. Journal of Virology. 2008;82(12):5672-82.
78. Zheng Z, Chinnasamy N, Morgan RA. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. Journal of translational medicine. 2012;10:29.

Supporting information

S1 Fig. CRISPR-mediated knockout of HLA-I A,B,C surface expression via gene-editing of human- β 2 microglobulin.

(A) Schematic of a lentiviral vector encoding Cas9 together under CMV promoter (CMV) with single guide RNA (sgRNA). The vector has an FG12-derived backbone possessing a self-inactivating LTR, a central polypurine tract (cPPT), and a mutant Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE). T2A: self-cleaving 2A peptide of *Thosea asigna*. EGFP fused with Cas9 via T2A peptide (SpCas9-T2A-EGFP) serves as a transduction marker. sgRNA: specific for human- β 2 microglobulin (β 2MG) (5'-GAGTAGCGCGAGCACAGCTA-3') under the human U6 RNA pol III promoter (U6).

(B) Jurkat cells without (Δ KS) or with inducibly expressing HIV-1_{HXB2} envelope proteins (HXB2) were transduced with a non-integrating lentiviral vector encoding Cas9 together with β 2MG sgRNA, which contain integrase with a D64E mutation. These cells were stained with PE-conjugated anti-human HLA-I A,B,C antibody.

742

743 **S2 Fig. Comparison of anti-HIV-1 gene products against HIV-1 infections.**

744 **(A)** Schematic of a lentiviral vector encoding anti-HIV-1 chimeric antigen receptor (CAR)
745 under the murine stem cell virus promoter (MSCV). The vector has an FG12-derived
746 backbone possessing a self-inactivating LTR, a central polypurine tract (cPPT), and a
747 mutant Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE).
748 Dual: the vector encoding EGFP together with two anti-HIV-1 genes, sh516 targeting HIV-
749 1 LTR R region under 7SK promoter (7SK) [76] and three different fusion inhibitors (V2o,
750 AP3, or C46) under EF1- α promoter (EF1 α) or sh1005 under H1 promoter[56]. **(B)** Human
751 primary CD4⁺ T cells were positively selected by anti-human CD4 magnetic beads. Cells
752 were stimulated by anti-CD3/CD28 antibodies (1 μ g/ml each) for 24 hours in the presence
753 of 30 IU/ml of human IL-2 and transduced with above vectors. EGFP-positive populations
754 were enriched by FACS Aria II on day 3 post-vector transduction and infected by two
755 different HIV-1 strains—HIV-1_{NL4-3} or HIV-1_{NFN-SX}—at 100ng of HIV-1 p24 per one million
756 cells. HIV-1 p24 amounts in culture supernatant were titrated 6 days post-HIV-1 challenge.
757 Mock: non-lentiviral vector transduced cells.

Fig 1

Fig 2

Fig 3

A

Antibodies	Antibody structure	Target epitopes
3BNC117	scFv	CD4bs
10E8	scFv	MPER
PGT128	scFv	V3 loops
J3	sdAb	CD4bs
1H9	sdAb	CD4bs
2E7	sdAb	MPER
2H10	sdAb	MPER
J M4	sdAb	CD4i
1F10	sdAb	V3 loops

B

C

Fig 4

A

B

C

D

Fig 5

A

sdAbs	Targets
J3	CD4bs
1H9	CD4bs
2E7	MPER
2H10	MPER
JM4	CD4i
1F10	V3 Loop

B

C

D

Fig 6

S Fig 1

A

B

S Fig 2